Total Funding
36
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
141881
Selecta Biosciences is a clinical-stage biotechnology company with an unrelenting commitment to overcoming immunogenicity.
Acquired by 
Cartesian Therapeutics
David Abraham: General Counsel and Corporate SecretaryPast Role: United States Patent and Trademark Office (USPTO), Patent Examiner
Lloyd Johnston: Chief Operating Officer and Senior Vice President R&DPast Role: Selecta Biosciences, Senior Vice President Research, Development and Operations
About the Company
Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles.
It
was founded in 2008 and is headquartered in Watertown, Massachusetts.
